Division of Clinical Neurology, University of Nottingham, Nottingham, United Kingdom.
J Neuroimmunol. 2011 Jul;236(1-2):111-7. doi: 10.1016/j.jneuroim.2011.05.005. Epub 2011 Jun 8.
Interferon-β (IFN-β) is known to expand regulatory CD56(bright) natural killer (NK) cells in multiple sclerosis (MS). In this cross-sectional study we show that MS patients treated with IFN-β alone or in combination with low-dose prednisolone displayed increased proportion of all NK cell subsets in the active phase of the cell cycle (Ki-67+). There was no difference in NK cell apoptosis markers. In vitro experiments showed that both IFN-β and IFN-β in combination with corticosteroids increased the proportion of Ki-67(+) NK cells. This study, although limited, shows that treatment with IFN-β affects NK cell cycle without altering NK cell apoptosis in MS patients.
干扰素-β（IFN-β）已知可扩增多发性硬化症（MS）患者中的调节性 CD56（bright）自然杀伤（NK）细胞。在这项横断面研究中，我们表明，接受 IFN-β 单独或联合低剂量泼尼松龙治疗的 MS 患者在细胞周期的活跃期（Ki-67+）显示出所有 NK 细胞亚群比例增加。NK 细胞凋亡标志物无差异。体外实验表明，IFN-β 和 IFN-β联合皮质类固醇均可增加 Ki-67（+）NK 细胞的比例。这项研究虽然有限，但表明 IFN-β 治疗可影响 MS 患者 NK 细胞周期，而不改变 NK 细胞凋亡。
